Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine

被引：513

作者：

Valkonen, VP

Päivä, H

Salonen, JT

Lakka, TA

Lehtimäki, T

Laakso, J

Laaksonen, R

机构：

[1] Univ Helsinki, Dept Clin Pharmacol, SF-00250 Helsinki, Finland

[2] Univ Kuopio, Res Inst Publ Hlth, FIN-70211 Kuopio, Finland

[3] Inner Savo Hlth Ctr, Suonenjoki, Finland

[4] Tampere Univ Hosp, Dept Med, Tampere, Finland

[5] Tampere Univ Hosp, Lab Atherosclerosis Genet, Tampere, Finland

[6] Tampere Univ, FIN-33101 Tampere, Finland

来源：

LANCET | 2001年 / 358卷 / 9299期

基金：

芬兰科学院;

关键词：

D O I：

10.1016/S0140-6736(01)07184-7

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Asymmetrical dimethylarginine (ADMA) is an endogenous nitric oxide synthase Inhibitor, which has been suggested to be a novel independent risk factor for endothelial dysfunction and coronary heart disease. We investigated the association of ADMA concentration In serum with risk of acute coronary events. We did a prospective, nested, case-control study in middle-aged men from eastern Finland. In an analysis of men who did not smoke, those who were in the highest quartile for ADMA (>0.62 mu mol/L) had a 3.9-fold (95% CI 1.25-12.3, p=0.02) increase in risk of acute coronary events compared with the other quartiles. Our findings suggest that ADMA is a predictor of acute coronary events.

引用

页码：2127 / 2128

页数：2

共 5 条

[1] Asymmetric dimethylarginine (ADMA):: A novel risk factor for endothelial dysfunction -: Its role in hypercholesterolemia [J].